将Finasteride装载的微球纳入个性化微针中,以实现持续的皮肤透射输送
Wenzuo Luo1, Xingui Zhang1, Yingying Chu1
1School of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan 430070, P. R. China.
概括
这项研究引入了一种新型的微针贴片,用于输送费纳胺 (FNS) 治疗雄激素性脱发症 (AGA). 微针系统提供持续的药物释放,可能减少与口服费纳斯特相关的副作用.
科学领域:
- 生物材料科学 生物材料科学
- 皮肤病学 皮肤病学
- 药物输送系统 药物输送系统
背景情况:
- 口服费纳斯特 (FNS) 对于雄激素性脱毛 (AGA) 有效,但有副作用.
- 目前的限制阻碍了FNS对AGA的广泛临床使用.
- 需要改进药物输送方法,以提高疗效和减少不良影响.
研究的目的:
- 开发一个个性化的微针 (PMN) 系统,用于持续的费纳斯特 (FNS) 输送.
- 为了克服FNS口服治疗雄激素脱发症 (AGA) 的局限性.
- 通过一种基于微针的新方法来减少与费纳斯特相关的副作用.
主要方法:
- 使用氨酸 (HA) 和甲酸凝 (GelMA) 制造双层微针.
- 将FNS装载的微球 (MP) 纳入微针结构.
- 评估药物释放动力学,皮肤透和细胞毒性.
主要成果:
- 开发的PMN系统证明了FNS的持续和受监管的释放.
- 微针成功透到角层,有效地输送药物.
- 细胞毒性测定证实了PMN系统的良好的细胞相容性.
结论:
- 个性化的微针系统为AGA治疗中芬纳的输送提供了一个有前途的替代方案.
- 这种方法显示了减少费纳斯特的副作用的潜力.
- 微针技术在医疗领域广泛适用于输送其他药物.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Site-Targeted Drug Delivery Systems: Polymeric Carriers
160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
Transdermal Drug Delivery Systems
233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
Intrauterine Drug Delivery Systems
168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168


